市场调查报告书
商品编码
1500568
尿液检查市场:按产品类型、应用、最终用途划分 - 2024-2030 年全球预测Urinalysis Market by Product (Consumables, Instruments), Test Type (Biochemical Urinalysis, Pregnancy & Fertility Tests, Sediment Urinalysis), Application, End-Use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
尿液检查市场规模预计2023年为43亿美元,2024年达到45.3亿美元,预计2030年将达到63.7亿美元,复合年增长率为5.76%。
尿液检查是对尿液样本进行的测试,通常用于医学筛检和诊断。该测试包括评估尿液的物理、化学和微观特性的各种元素。分析这些特征可以帮助检测各种疾病,例如尿道感染、肾臟疾病和糖尿病。通常有三种类型的测试:目视测试,查看尿液的颜色和透明度;化学测试,寻找蛋白质、葡萄糖和血液等物质;以及显微镜测试,寻找尿液中看不见的因素。细菌的存在,将进行两项测试。全球范围内肾臟疾病和尿道感染的增加导致临床实践中照护现场(POC) 系统的使用增加。这些系统提供快速且有效率的分析,导致医院和实验室的采用增加,支持市场成长。然而,需要提高人们对定期健康检查重要性的认识,并且缺乏熟练的实验室工作人员正在阻碍尿液检查市场的成长。用于检测尿道感染的自动分析仪的开发是一项重要的技术进步,可以提供快速、准确的检测。随着医疗保健提供者越来越多地采用这些高效可靠的系统,这将改善患者照护并为市场扩张开闢新的机会。这些创新预计将透过满足对及时有效的诊断解决方案不断增长的需求来推动市场扩张。
主要市场统计 | |
---|---|
基准年[2023] | 43亿美元 |
预计年份 [2024] | 45.3亿美元 |
预测年份 [2030] | 63.7亿美元 |
复合年增长率(%) | 5.76% |
区域洞察
由于先进的医疗基础设施、高额医疗支出以及对预防性医疗的高度重视,美洲的尿液检查市场非常强劲,尤其是在美国和加拿大。肾臟病和糖尿病等慢性疾病的盛行率不断上升,需要定期尿液检查,这对市场成长做出了重大贡献。政府和医疗机构加强诊断服务的努力正在支持该地区尿液检查市场的扩张。由于中国和印度等医疗意识的提高、人口的成长和经济的开拓,亚太地区的尿液检查市场呈现快速成长。亚太地区有大量糖尿病患者,透过尿液检查频繁监测血糖浓度的需求也推动了市场成长。此外,由于劳动力限制和对高效医疗保健解决方案的需求,向自动化尿液检查系统的转变也加剧了这种成长。由于医疗保健意识的提高、诊断技术的进步以及糖尿病和尿道感染等疾病盛行率的上升,欧洲、中东和非洲地区的尿液检查市场正在呈现成长。欧盟用于改善诊断技术的研究经费反映了其改善成员国医疗保健成果的承诺。随着人们对尿道感染和糖尿病等疾病的认识不断提高,非洲尿液检查市场也逐渐扩大。
FPNV定位矩阵
FPNV 定位矩阵对于评估尿液检查市场供应商的定位至关重要。此矩阵提供了对供应商的全面评估,并检验了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对尿液检查市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外,该分析还提供了对该行业竞争力的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
战略分析和建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在尿液检查市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[187 Pages Report] The Urinalysis Market size was estimated at USD 4.30 billion in 2023 and expected to reach USD 4.53 billion in 2024, at a CAGR 5.76% to reach USD 6.37 billion by 2030.
Urinalysis is a test conducted on a urine sample and is commonly used for medical screening and diagnosis. The test encompasses various components that assess the urine's physical, chemical, and microscopic properties. By analyzing these properties, the test helps in detecting various disorders, such as urinary tract infections, kidney disease, and diabetes. The process typically involves three examinations: a visual exam, which observes the urine's color and clarity; a chemical exam, which tests chemically for substances such as protein, glucose, and blood; and a microscopic exam, which looks for cells, bacterial presence, and other elements that are not visible to the naked eye. The increasing incidence of kidney diseases and urinary tract infections globally leads to higher use of point-of-care urinalysis systems in clinical settings. These systems offer quick and efficient analysis, which propels their adoption in hospitals and labs, thus supporting the market's growth. However, the need for more awareness about the importance of regular health checkups and a shortage of skilled laboratory staff hinder the growth of the urinalysis market. The development of automated analyzers for detecting urinary tract infections represents a significant technological advancement, offering rapid and accurate testing. This improves patient care and opens up new opportunities for market expansion as healthcare providers increasingly adopt these efficient and reliable systems. These innovations are expected to propel market expansion by fulfilling the rising demand for timely and effective diagnostic solutions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 4.30 billion |
Estimated Year [2024] | USD 4.53 billion |
Forecast Year [2030] | USD 6.37 billion |
CAGR (%) | 5.76% |
Regional Insights
In the Americas, particularly in the United States and Canada, the urinalysis market is robust due to the advanced healthcare infrastructure, high healthcare spending, and a strong focus on preventive care. The growing prevalence of chronic diseases, such as kidney disorders and diabetes requiring regular urine tests, contributes significantly to the market growth. Government and health organizations' initiatives to enhance diagnostic services support the expansion of the urinalysis market in this region. The Asia-Pacific region is showcasing rapid growth in the urinalysis market, driven by rising healthcare awareness, increasing population, and economic development in countries such as China and India. The Asia-Pacific region's large diabetic population, which requires frequent glucose level monitoring through urine tests, also propels market growth. In addition, the shift towards automated urinalysis systems due to labor constraints and the need for efficient healthcare solutions accentuates this growth. The urinalysis market in the EMEA region is showcasing growth owing to increasing healthcare awareness, advancements in diagnostic technologies, and a rising prevalence of diseases, including diabetes and urinary tract infections. EU funding for research in improving diagnostic technologies reflects a committed approach to enhancing healthcare outcomes across member states. The African urinalysis market is gradually growing with increased awareness about diseases such as urinary tract infections and diabetes.
Market Insights
The market dynamics represent an ever-changing landscape of the Urinalysis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Urinalysis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Urinalysis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
AixMed and CorePlus Collaborate on Innovative Urine Analysis Research
AixMed partnered with CorePlus for an innovative study focusing on urine analysis to enhance diagnostic accuracy for various diseases. This partnership leverages CorePlus laboratories' capabilities and AixMed's expertise in medical diagnostics technology to revolutionize how diseases are detected and monitored potentially. This initiative aims to contribute valuable insights into disease mechanisms and patient health management. [Published On: 2024-04-18]
Toyoda Gosei Invests in Yuurea Inc. for Advancement in Urine Analysis Technology
Toyoda Gosei Co., Ltd. strategically invested in Yuurea Inc., an innovative startup specializing in the development of urine test kits aimed at early detection of eating disorders. Yuurea Inc.'s urine test kits represent a significant advancement in medical diagnostics, offering a non-invasive and timely method for identifying potential eating disorders, thereby facilitating earlier intervention and treatment. [Published On: 2024-03-25]
Medtronic's Strategic Initiative to Address Urinary Incontinence with New Venture
Medtronic, a medical technology, service, and solutions provider, recently unveiled a new venture specifically aimed at advancing treatments for urinary incontinence, expanding its portfolio in medical technology solutions. This develops the company's commitment to address widespread health concerns by investing in innovative and effective treatments. [Published On: 2023-04-03]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Urinalysis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Urinalysis Market, highlighting leading vendors and their innovative profiles. These include 77 Elektronika Kft., Abbott Laboratories, ACON Laboratories, Inc. by Inverness Medical, AdvaCare Pharma, Alphatec Scientific E.I.R.L., Analyticon Biotechnologies GmbH by BRAIN Biotech AG, Anamol Laboratories Pvt. Ltd., ARKRAY, Inc., Beckman Coulter, Inc. by Danaher Corporation, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Bioway Biotechnology Co., Ltd., Cardinal Health, Inc., Contec Medical Systems Co., Ltd., Dirui Industrial Co., Ltd., EKF DIAGNOSTICS HOLDINGS PLC, Erba Group, F. Hoffmann-La Roche Ltd., Kova International, Inc. by LGC Limited, MACHEREY-NAGEL GmbH & Co. KG, Medsource Ozone Biomedicals Pvt. Ltd., Quidel Corporation, Randox Laboratories Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthcare GmbH, Sweet Cures Nutra, Sysmex Corporation, Teco Diagnostics, Thermo Fisher Scientific Inc., URIT Medical Electronic Group Co., Ltd, and Woodley Equipment Company Ltd..
Market Segmentation & Coverage
chronic diseases